Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Rosetta Genomics to Beef Up Israel Research Building

  • Rosetta Genomics is expanding its Israeli research facility to include new laboratories for its microRNA-based diagnostic programs. The company expects to grow to approximately 70 employees by the end of the year.

    "This expansion will enable us to advance new development programs and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," says Amir Avniel, CEO. "Our proprietary discovery platform is capable of utilizing over 12,000 predicted and validated microRNAs, including over 1,000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »